The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is sure to face legal challenges, experts say.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

The company established a new protocol for the study and will advance its drug response predictor as a companion diagnostic.

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

The firm is evaluating two dose levels of its nectin-4-targeted ADC plus Merck's Keytruda in a range of solid tumors.